The Global Partnership for Zero Leprosy (GPZL) is seeking nominations for Representatives of National Leprosy Programs to serve on its Members’ Assembly for a two-year term, renewable once. The term will begin on 1 April 2025.
With the support of GPZL partner organizations, the consultant will conduct a comprehensive assessment of MDT, Clofazimine, Prednisolone, and Rifampicin supply chain challenges in the selected countries, identifying inefficiencies, key barriers, and opportunities for improvement.
Our 2020 impact report highlights our work in COVID-19 response, leprosy research, and country partnerships.
DownloadVisit the Zero Leprosy COVID-19 hub for the latest advice, resources, and news related to leprosy during the COVID-19 pandemic.
Visit site“In order to bring down the case detection among leprosy contacts from Point A to Point B, programmes can choose to treat 100 contacts with leprosy and nobody with chemoprophylaxis or provide chemoprophylaxis to all contacts and treat only 43 leprosy patients”. The latter choice is the most obvious for many programmes. This document provides guidance on how to implement contact screening and chemoprophylaxis with single-dose rifampicin. The contents are logically ordered: counselling and obtaining consent, identification and listing of index case, listing of contacts, tracing of contacts, screening of contacts, administration of prophylactic drugs. Managerial aspects to undertake contact screening and chemoprophylaxis are also elaborated, including planning, training, supervision and drug management.
Visit site